Kiora Pharmaceuticals Inc (KPRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kiora Pharmaceuticals Inc (KPRX) has a cash flow conversion efficiency ratio of -0.227x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.16 Million) by net assets ($13.93 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Kiora Pharmaceuticals Inc's balance sheet to measure how much of total assets are equity-financed.
Kiora Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Kiora Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Kiora Pharmaceuticals Inc cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Kiora Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kiora Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CVS Group Plc
LSE:CVSG
|
0.145x |
|
Sambo Industrial
KQ:009620
|
-0.150x |
|
Progressive Impact Corporation Bhd
KLSE:7201
|
0.520x |
|
Episurf Medical AB (publ)
ST:EPIS-B
|
-0.244x |
|
MITCON Consultancy & Engineering Services Limited
NSE:MITCON
|
0.147x |
|
Big Rock Brewery Inc.
TO:BR
|
-0.021x |
|
SL Private Equity
LSE:SLPE
|
-0.001x |
|
EV RESOURCES LTD.
F:R1EA
|
N/A |
Annual Cash Flow Conversion Efficiency for Kiora Pharmaceuticals Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Kiora Pharmaceuticals Inc from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see KPRX market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $16.13 Million | $-9.96 Million | -0.618x | -285.90% |
| 2024-12-31 | $25.76 Million | $8.56 Million | 0.332x | +121.24% |
| 2023-12-31 | $6.11 Million | $-9.56 Million | -1.564x | -71.12% |
| 2022-12-31 | $11.41 Million | $-10.43 Million | -0.914x | -24.84% |
| 2021-12-31 | $14.58 Million | $-10.68 Million | -0.732x | +2.63% |
| 2020-12-31 | $9.73 Million | $-7.32 Million | -0.752x | +38.92% |
| 2019-12-31 | $6.62 Million | $-8.15 Million | -1.231x | -1.46% |
| 2018-12-31 | $8.94 Million | $-10.84 Million | -1.214x | -136.15% |
| 2017-12-31 | $-1.93 Million | $-6.47 Million | 3.357x | -86.86% |
| 2016-12-31 | $-329.42K | $-8.41 Million | 25.539x | +3586.11% |
| 2015-12-31 | $6.09 Million | $-4.46 Million | -0.733x | -3184.65% |
| 2014-12-31 | $-40.03 Million | $-950.62K | 0.024x | -69.25% |
| 2013-12-31 | $-38.29 Million | $-2.96 Million | 0.077x | -48.50% |
| 2012-12-31 | $-34.81 Million | $-5.22 Million | 0.150x | -- |
About Kiora Pharmaceuticals Inc
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also deve… Read more